it received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, or TRG, in response to the Company’s requests regarding its Natalin and Acelagraft ...
Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...
and other agencies to confirm the regulatory status of an HCT/P and that it meets the criteria for regulation solely under Section 361 of the Public Health Services Act, versus requiring premarket ...
Post-HCT maintenance therapies were allowed if planned to initiate after day 90 post-transplant, given conclusion of study drug administration around this time. Use of antithymocyte globulin or ...
TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...
In May 2024, the U.S. Food and Drug Administration (FDA ... in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Based on a ...
Celularity (CELU) received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, or TRG, in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback